Endosomal Proteolysis of the Ebola Virus Glycoprotein Is Necessary for Infection
Author(s) -
Kartik Chandran,
Nancy J. Sullivan,
Ute Felbor,
Sean P. J. Whelan,
James M. Cunningham
Publication year - 2005
Publication title -
science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 12.556
H-Index - 1186
eISSN - 1095-9203
pISSN - 0036-8075
DOI - 10.1126/science.1110656
Subject(s) - ebola virus , filoviridae , virology , cathepsin l , vero cell , biology , cathepsin b , proteases , endosome , vesicular stomatitis virus , ebolavirus , mononegavirales , protease , glycoprotein , virus , enzyme , microbiology and biotechnology , cell , viral disease , paramyxoviridae , biochemistry
Ebola virus (EboV) causes rapidly fatal hemorrhagic fever in humans and there is currently no effective treatment. We found that the infection of African green monkey kidney (Vero) cells by vesicular stomatitis viruses bearing the EboV glycoprotein (GP) requires the activity of endosomal cysteine proteases. Using selective protease inhibitors and protease-deficient cell lines, we identified an essential role for cathepsin B (CatB) and an accessory role for cathepsin L (CatL) in EboV GP-dependent entry. Biochemical studies demonstrate that CatB and CatL mediate entry by carrying out proteolysis of the EboV GP subunit GP1 and support a multistep mechanism that explains the relative contributions of these enzymes to infection. CatB and CatB/CatL inhibitors diminish the multiplication of infectious EboV-Zaire in cultured cells and may merit investigation as anti-EboV drugs.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom